BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Senefeld JW, Klassen SA, Ford SK, Senese KA, Wiggins CC, Bostrom BC, Thompson MA, Baker SE, Nicholson WT, Johnson PW, Carter RE, Henderson JP, Hartman WR, Pirofski LA, Wright RS, Fairweather L, Bruno KA, Paneth NS, Casadevall A, Joyner MJ. Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion 2021;61:2503-11. [PMID: 34036587 DOI: 10.1111/trf.16525] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Garraud O, Burnouf T. Convalescent Covid-19 plasma: Back-to-basics and ethics, and next steps. Transfus Clin Biol 2021;28:225-7. [PMID: 34362557 DOI: 10.1016/j.tracli.2021.07.005] [Reference Citation Analysis]
2 Vachtenheim J Jr, Novysedlak R, Svorcova M, Lischke R, Strizova Z. How COVID-19 Affects Lung Transplantation: A Comprehensive Review. J Clin Med 2022;11:3513. [PMID: 35743583 DOI: 10.3390/jcm11123513] [Reference Citation Analysis]
3 Steiner S, Schwarz T, Corman VM, Gebert L, Kleinschmidt MC, Wald A, Gläser S, Kruse JM, Zickler D, Peric A, Meisel C, Meyer T, Staudacher OL, Wittke K, Kedor C, Bauer S, Besher NA, Kalus U, Pruß A, Drosten C, Volk HD, Scheibenbogen C, Hanitsch LG. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity. Front Immunol 2022;13:840126. [PMID: 35359967 DOI: 10.3389/fimmu.2022.840126] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Fouka E, Kalomenidis I, Gianniou N, Gida S, Steiropoulos P. COVID-19 Advanced Care. J Pers Med 2021;11:1082. [PMID: 34834434 DOI: 10.3390/jpm11111082] [Reference Citation Analysis]
5 Taha Y, Wardle H, Evans AB, Hunter ER, Marr H, Osborne W, Bashton M, Smith D, Burton-Fanning S, Schmid ML, Duncan CJA. Persistent SARS-CoV-2 infection in patients with secondary antibody deficiency: successful clearance following combination casirivimab and imdevimab (REGN-COV2) monoclonal antibody therapy. Ann Clin Microbiol Antimicrob 2021;20:85. [PMID: 34969393 DOI: 10.1186/s12941-021-00491-2] [Reference Citation Analysis]
6 Ravlić S, Hećimović A, Kurtović T, Ivančić Jelečki J, Forčić D, Slović A, Kurolt IC, Mačak Šafranko Ž, Mušlin T, Rnjak D, Jakšić O, Sorić E, Džepina G, Đaković Rode O, Kujavec Šljivac K, Vuk T, Jukić I, Markotić A, Halassy B. Is Better Standardization of Therapeutic Antibody Quality in Emerging Diseases Epidemics Possible? Front Immunol 2022;13:816159. [PMID: 35273599 DOI: 10.3389/fimmu.2022.816159] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Avery RK. Update on COVID-19 Therapeutics for Solid Organ Transplant Recipients, Including the Omicron Surge. Transplantation 2022;106:1528-37. [PMID: 35700481 DOI: 10.1097/TP.0000000000004200] [Reference Citation Analysis]
8 Garcia-Muñoz R, Farfán-Quiroga G, Ruiz-de-Lobera N, Feliu J, Anton-Remirez J, Nájera Irazu MJ, Lisa Catón V, Oteo-Revuelta JA. Serology-based therapeutic strategy in SARS-CoV-2-infected patients. Int Immunopharmacol 2021;101:108214. [PMID: 34649116 DOI: 10.1016/j.intimp.2021.108214] [Reference Citation Analysis]
9 Spinicci M, Mazzoni A, Coppi M, Antonelli A, Salvati L, Maggi L, Basile G, Graziani L, Di Lauria N, Di Pilato V, Kiros ST, Beccastrini E, Saccardi R, Angileri M, Cecchi M, Cusi MG, Rossolini GM, Annunziato F, Bartoloni A, Parronchi P. Long-term SARS-CoV-2 Asymptomatic Carriage in an Immunocompromised Host: Clinical, Immunological, and Virological Implications. J Clin Immunol 2022. [PMID: 35779200 DOI: 10.1007/s10875-022-01313-6] [Reference Citation Analysis]
10 Focosi D, Franchini M, Pirofski LA, Burnouf T, Paneth N, Joyner MJ, Casadevall A. COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes. Clin Microbiol Rev 2022;:e0020021. [PMID: 35262370 DOI: 10.1128/cmr.00200-21] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
11 Stauft CB, Tegenge M, Khurana S, Lee Y, Selvaraj P, Golding H, Wang T, Golding B. Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of SARS-CoV-2 Infection in Adult Syrian Hamsters. Clin Infect Dis 2021:ciab854. [PMID: 34554235 DOI: 10.1093/cid/ciab854] [Reference Citation Analysis]
12 Joyner MJ, Klompas AM, Klassen SA, Senefeld JW, Fairweather D, Wright RS, Carter RE. In Reply-How Safe Is COVID-19 Convalescent Plasma? Mayo Clin Proc 2021;96:2281-2. [PMID: 34353476 DOI: 10.1016/j.mayocp.2021.06.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Metcalf RA, Cohn CS, Allen ES, Bakhtary S, Gniadek T, Gupta G, Harm S, Haspel R, Hess A, Jacobson J, Lokhandwala PM, Murphy C, Poston J, Prochaska MT, Raval JS, Saifee NH, Salazar E, Shan H, Zantek N, Pagano MB. Current advances in transfusion medicine 2021: A critical review of selected topics by the AABB Clinical Transfusion Medicine Committee. Transfusion 2022. [PMID: 35713186 DOI: 10.1111/trf.16944] [Reference Citation Analysis]
14 Feldman AG, Danziger-isakov LA. The Impact of COVID-19 on the Pediatric Solid Organ Transplant Population. Seminars in Pediatric Surgery 2022. [DOI: 10.1016/j.sempedsurg.2022.151178] [Reference Citation Analysis]
15 Klompas AM, van Helmond N, Juskewitch JE, Pruthi RK, Sexton MA, Soto JCD, Klassen SA, Senese KA, van Buskirk CM, Winters JL, Stubbs JR, Hammel SA, Joyner MJ, Senefeld JW. Coagulation profile of human COVID-19 convalescent plasma. Sci Rep 2022;12:637. [PMID: 35022488 DOI: 10.1038/s41598-021-04670-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hartmann J, Bloch EM, Burnouf T. Experience with COVID ‐19 convalescent plasma provides vital guidance to future pandemics. Transfusion. [DOI: 10.1111/trf.16810] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 van de Veerdonk FL, Giamarellos-Bourboulis E, Pickkers P, Derde L, Leavis H, van Crevel R, Engel JJ, Wiersinga WJ, Vlaar APJ, Shankar-Hari M, van der Poll T, Bonten M, Angus DC, van der Meer JWM, Netea MG. A guide to immunotherapy for COVID-19. Nat Med 2022. [PMID: 35064248 DOI: 10.1038/s41591-021-01643-9] [Cited by in Crossref: 29] [Cited by in F6Publishing: 20] [Article Influence: 29.0] [Reference Citation Analysis]
18 Ordaya EE, Abu Saleh OM, Stubbs JR, Joyner MJ. Vax-Plasma in Patients With Refractory COVID-19. Mayo Clin Proc 2022;97:186-9. [PMID: 34996552 DOI: 10.1016/j.mayocp.2021.11.001] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
19 Belov A, Huang Y, Villa CH, Whitaker BI, Forshee R, Anderson SA, Eder A, Verdun N, Joyner MJ, Wright SR, Carter RE, Hung DT, Homer M, Hoffman C, Lauer M, Marks P; Broad Institute COVID-19 Antibody Team. Early administration of COVID-19 convalescent plasma with high titer antibody content by live viral neutralization assay is associated with modest clinical efficacy. Am J Hematol 2022;97:770-9. [PMID: 35303377 DOI: 10.1002/ajh.26531] [Reference Citation Analysis]
20 Benites BD, Costa-Lima C, Pinto FBR, da Costa VA, Duarte ADSS, Zangirolami AB, Amaro EC, Granja F, Proenca-Modena JL, Saad STO, Addas-Carvalho M. Selection of plasma donors for the production of anti-SARS-CoV-2 immunoglobulin-based therapies: Strategies for quantitative antibody measurements. Transfus Apher Sci 2022;:103513. [PMID: 35871137 DOI: 10.1016/j.transci.2022.103513] [Reference Citation Analysis]
21 Razumikhin M, Smolyanova T, Nikolaeva A, Orlova E, Ivanov A, Belyakova O, Vyaznikova T, Selezneva N, Perevozchikov A, Sokolova A, Zubkova N, Efimova I, Dolzhikova I, Logunov D, Sakanjan E. Development and characterization of anti-SARS-CoV-2 intravenous immunoglobulin from COVID-19 convalescent plasma. Immunotherapy 2022. [PMID: 35892311 DOI: 10.2217/imt-2022-0015] [Reference Citation Analysis]
22 Paneth N, Casadevall A, Pirofski L, Henderson JP, Grossman BJ, Shoham S, Joyner MJ. WHO covid-19 drugs guideline: reconsider using convalescent plasma. BMJ. [DOI: 10.1136/bmj.o295] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]